Research Interest:

Two Major Projects are Currently Underway in the Laboratory.
A Cell Reprogramming Technique Has Been Used to Convert Heterogeneous Malignant Breast Cancer Cells into Induced Pluripotent Stem Cells Using Sox2/Oct4/Nanog Proteins. Dr. Wu’s Laboratory is Clarifying these Induced Pluripotent Stem Cells for their Differentiation Potential and Oncogenic Properties, and Try to Develop a Novel Cell Converting Therapy for Malignant Breast Cancer Treatment.
Metastasis, the Spread of Cancer Cells from the Primary Tumor To Distant Organs, Is The Most Dreadful Development Of Breast Cancer, As Well As Other Neoplastic Diseases. Although Metastasis Contributes To Over 90% Of Human Cancer Mortality, The Molecular Mechanism Of This Process Remains Largely Unknown. Dr. Wu’s Laboratory Is In The Process Of Identifying Molecular Signatures Involved In Breast Cancer Metastasis Using Integrative Genetic, Epigenetic And Proteomic Approach, As Well As Animal Models And Clinical Specimens. 

Research Interest: Regenerative Biology (Marine Invertebrates and Mammals), Stem Cell Biology, Developmental Biology.

Research Interest: Clinical Pharmacology, Gastroenterology, Pharmaceutical Development, Drug Development, Colorectal Cancer, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease

Research Interest: Neurology

Research Interest: Embryonic Stem Cells, Pluripotency, Induced Pluripotent Cells, Differentiation, Endoderm, Beta Cell, Diabetes, Obesity, Adipose Tissue, Brown Fat, Endothelium, Oxidative Stress, Nitric Oxide, Peroxynitrite, Superoxide, Nanosensors.

Research Interest: Fate Decisions of Embryonic Stem Cell, Induced Pluripotent Stem Cell (ESC/Ips): Pluripotency and Direct Lineage Specification to the Three Germ Layers.

Dr. Edgar Grinstein is a Principal Investigator at the Heinrich Heine University in Düsseldorf (Germany). He researches hematopoietic stem cells and progenitor cells, signal transduction, gene transcription regulation. He has more than 11 years of experience as Editor-In-Chief at SAGE Publications Inc. (USA) and Libertas Academica (New Zealand), and also serves as Deputy Editor-In-Chief for Baishideng Publishing Group (USA).

Raised in a family of researchers – both parents are PhD scientists - he received his PhD summa cum laude in Molecular Biology from the Humboldt University and the Max-Delbrück Center for Molecular Medicine in Berlin. He has published a number of papers in high-ranking journals and received a highly regarded Research Award from Dr.-Günther- and Imme-Wille-Foundation. Dr. Grinstein qualified as Professor in Molecular Medicine at the University of Düsseldorf in 2008 and is a Visiting Professor at the University of Latvia (Latvia, European Union) since 2010.  

Dr. Grinstein`s research in the field of hematopoietic stem and progenitor cells, funded by research grants from German Research Foundation (DFG) and José Carreras Leukämie-Stiftung (José Carreras Foundation), has focused on markers, signal transduction and transcriptional control. Among other important findings made, his research group provided new insights into the role of the prominent surface marker AC133/CD133 (Leukemia 2015; 29: 2208-2220), that is expressed on stem/progenitor cells in normal hematopoiesis as well as on tumor-initiating cells in certain hematological malignancies. The study analyzed the control of AC133/CD133 expression in hematopoietic stem/progenitor cells, and revealed the impact thereof on molecular network relevant to these cells.

Research Interest: hematopoietic stem cells and progenitor cells, cancer stem cells, stem cell markers, signal transduction, cell cycle control, regulation of apoptosis, gene transcription regulation

Grants: Principal Investigator of stem cell-related projects funded by German Research Foundation (DFG) and by José Carreras Leukämie-Stiftung (José Carreras Foundation)

URL: https://www.wjgnet.com/2218-6204/MemberDetail/42530

publications:

Grinstein, E., and H.-D. Royer. 1995. Multiple octamer-binding proteins are targets for the cell cycle regulated nuclear inhibitor I-92. DNA Cell Biol. 14: 493-500.

Grinstein, E., I. Weinert, B. Droese, M. Pagano, and H.-D. Royer. 1996. Cell cycle regulation of nuclear factor p92 DNA-binding activity by novel phase-specific inhibitors. J. Biol. Chem. 271: 9215-9222.

Bargou, R.C., C. Wagener, K. Bommert, W. Arnold, P.T. Daniel, M.Y. Mapara, E. Grinstein, H.-D. Royer, and B. Dörken. 1996. Blocking of transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis and induces tumor growth in SCID mice. J. Exp. Med. 183: 1205-1213.

Bargou, R.C., F. Emmerich, D. Krappmann, K. Bommert, M.Y. Mapara, W. Arnold, H.-D. Royer, E. Grinstein, A. Greiner, C. Scheidereit, and B. Dörken. 1997. Constitutive nuclear factor kappaB-RelA activation is required for proliferation and survival of Hodkin’s desease tumor cells. J. Clin. Invest. 12: 2961-2969.

Janke, J., K. Schlüter, B. Jandrig, M. Theile, K. Kölble, W. Arnold, E. Grinstein, A.  Schwartz, L.E. Schwarz, P.M. Schlag, B.M. Jockusch, and S. Scherneck. 2000. Suppression of tumoriginecity in breast cancer cells by the microfilament protein profilin1. J. Exp. Med. 191: 1675-1685.

Grinstein, E.,* F. Jundt, I. Weinert, P. Wernet, and H.-D. Royer. 2002. Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene. 21: 1485-1492.

Grinstein, E., P. Wernet, P.J. Snijders, F. Rösl, I. Weinert, W. Jia, R. Kraft, Ch. Schewe, M. Schwabe, S. Hauptmann, M. Dietel, Ch. Meijer, and H.-D. Royer. 2002. Nucleolin as activator of human papillomavirus type 18 oncogene transcription in cervical cancer. J. Exp. Med. 196: 1067-1078.

Grinstein, E.,* Y. Shan, L. Karawajew, P.J. Snijders, C.J. Meijer, H.-D. Royer, and P. Wernet. 2006. Cell cycle controlled interaction of nucleolin with the retinoblastoma protein and cancerous cell transformation.  J. Biol. Chem. 281: 22223-22235.

Grinstein, E.,* Y. Du, S. Santourlidis, J. Christ, M. Uhrberg, and P. Wernet. 2007. Nucleolin regulates gene expression in CD34 positive hematopoietic cells. J. Biol. Chem. 282: 12439-12449.

Grinstein, E.,* and P. Wernet. 2007. Cellular signaling in normal and cancerous stem cells. Cell. Signal. 19: 2428-2433.
This was the most read article of the Journal Cell. Signal. from July 2007 till March 2008. Source: SCIENCEDIRECT TOP 25 HOTTEST ARTICLES

Wethkamp, N., H. Hanenberg, C. Suschek, W. Wetzel, S. Heikaus, E. Grinstein, U. Ramp, R. Engers, H. Gabbert, and C. Mahotka. 2011. DAXX-beta and DAXX-gamma: two novel splice variants of the transcriptional co-repressor DAXX. J. Biol. Chem. 19576-19588.

Grinstein, E.,* C. Mahotka, and A. Borkhardt. 2011. Rb and nucleolin antagonize in controlling human CD34 gene expression. Cell. Signal. 23: 1358-1365.

Bhatia, S., S. Reister, C. Mahotka, R. Meisel, A. Borkhardt, and E. Grinstein.* 2015. Control of AC133 / CD133 and impact on human hematopoietic progenitor cells through nucleolin. Leukemia. 29: 2208-2220.

Mahotka, C., S. Bhatia, J. Kollet, and E. Grinstein.* 2018. Nucleolin promotes execution of the hematopoietic stem cell gene expression program. Leukemia. 32: 1865–1868.

Reister, S., C. Mahotka, N. van den Höfel, and  E. Grinstein.* 2019. Nucleolin promotes Wnt signaling in human hematopoietic stem/progenitor cells. Leukemia. 33: 1052-1054.

Research Interest: Cancer Stem Cells, Ocular Stem Cells

Research Interest: Cancer Stem Cell, Anticancer Agent, Metastasis, Cell Survival, Cell Migration, Apoptosis, Molecular and Cell Signaling, Transcription Factors, Xenograft Model, Stem Cell Based Therapy.

Research Interest: Neurological Disability.

Research Interest: During those Years She Extended her Initial Research Interests on Endothelial Progenitor Cell (EPC) Biology and their Potential use in Regenerative Medicine. 

Research Interest: Centered on Translational Oncology with Main Emphasis on Identification of Novel Targets in Cancer Stem Cells, Validation of Targeted Cancer Therapeutics, Nanomedicine and Drug Development Program.

Research Interest: Cancer Biology, Cell Biology, Breast Cancer, Cancer Prevention, Anti-Cancer Drug Development, Cancer Metastasis, Transcription Factors, Kinase, Glucose Metabolism.

Research Interest: Drug Discovery and Development.

Research Interest: As Is Clear From The Biography, Shigetaka Asano Accomplisheddistinguished Performance In Research Based On Medical Needs By Full Of Enthusiasm With State-Of-The-Art New Technology, Such As 1. Verification Of Existence Of Rabbit Neutrophil Cell Membrane Knack+-Atpase, 2. Discovery Of Laterarity Of Mouse Intestinal Mucous Membrane Proteins, 3. Finding Of Human Tumor Cell Mediated By Granulocyte Colony-Stimulating Factor (G-CSF; Bioactive Substance To Stimulate Differentiation, Proliferation And Functional Activity Of Neutrophil), 4. Analysis Of Human G-CSF Activity, 5. Succeeding In Incubation Of Human Tumor Infiltrating T Lymphocyte Colony, 6. Discovery Of Allogenicimmunosuppression Of Placenta Decidual Cells, 7. Differentiation Induction Of Mesenchymalstem Cell, 8. Cloning Of G-Csfcdna And Development Of Recombinant Human Native G-CSF (Lenograstim) As The 1st Generation Biomedicine, 9. Constitution Of International Clinical Guideline For Transplantation Of Bone-Marrow And Cord Blood, And Construction Of Public Bank Of Bone-Marrow And Cord Blood, 10. Non-Clinical Study Of Human Granulocyte Colony-Stimulating Factor (GM-CSF; Bioactive Substance To Stimulate Differentiation, Proliferation And Functional Activity Of Macrophage Besides Neutrophil)Immunogene Therapy And Execution Of The Phase Iia Clinical Study, 11. Non-Clinical Study Of Utilizing Maxizyme For Immunogene Therapy Of Myeloid Leukemia Cell, 12. Acquisition And Molecular Analysis Of Leukemia Stem Cell Like Property By Stochastic Adhesion Of In Vitro Human Myelogenous Leukemic Cell Line Cell And Stromal Cell, 13. Pathological Analysis Of Mesenchymalstem Cell(Parental Cell Of Range Of Cell Consist Ofstroma) Differentiation And Proliferation In Translin(Substance Found As Molecule To Bind Fusion Gene Of Lymphatic Leukemia) Knockout Mouse.